Ortho Firms Feel DoJ Probe Price As Stocks Fall In Q1; Will Zimmer Diversify?
This article was originally published in The Gray Sheet
Executive Summary
The federal government's mounting scrutiny of orthopedic industry pricing practices for hip and knee replacement implants could convince Zimmer to more aggressively seek a presence in the artificial disc arena